期刊
FRONTIERS IN IMMUNOLOGY
卷 12, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2021.780145
关键词
chimeric; allogeneic; clinical; trials; GvHD; receptor; T cell; CAR (chimeric antigen receptor)
类别
资金
- Ministry of Science and Higher Education of the Russian Federation [075-15-2020-901]
Despite the successful results of autologous CAR-T cell therapy in hematological malignancies, there are limitations in manufacturing and safety concerns. Allogeneic CAR-T cells have the potential to address these issues, but also come with potential risks. Researching new strategies to create an allogeneic product that circumvents these limitations is an active area of study.
Despite the outstanding results of treatment using autologous chimeric antigen receptor T cells (CAR-T cells) in hematological malignancies, this approach is endowed with several constraints. In particular, profound lymphopenia in some patients and the inability to manufacture products with predefined properties or set of cryopreserved batches of cells directed to different antigens in advance. Allogeneic CAR-T cells have the potential to address these issues but they can cause life-threatening graft-versus-host disease or have shorter persistence due to elimination by the host immune system. Novel strategies to create an off the shelf allogeneic product that would circumvent these limitations are an extensive area of research. Here we review CAR-T cell products pioneering an allogeneic approach in clinical trials.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据